28 results about "Biological immunity" patented technology

The invention belongs to the field of biological immunity, and discloses a linear B cell epitope of African swine fever virus NP419L protein and application. The epitope sequence shows good immunoreactivity through ASFV positive pig serum recognition verification. The African swine fever positive serum can be identified by using the B cell epitope identified by the invention to carry out ELISA (Enzyme-Linked Immunosorbent Assay) experiment, and the sensitivity of the African swine fever positive serum is superior to that of NP419L protein full length and other truncated fragments. The epitope identified by the invention has high conservative property in reference ASFV strains in a plurality of popular regions in China, and has wide universality and adaptability. The kit can be widely applied to etiological diagnosis, serological diagnosis, immunological detection and disease prevention and treatment of African swine fever viruses, and can be applied to preparation of African swine fever vaccines, pathogenesis research and the like.

The application belongs to the field of biological medicine, and particularly relates to a pharmaceutical composition for treating inflammatory bowel disease and application of the pharmaceutical composition. The disclosed pharmaceutical composition comprises anti-TNF monoclonal antibody, phosphoketolase-producing bacteria or a pharmaceutically acceptable viable bacterial preparation or extract thereof. The application comprehensively utilizes multi-dimensional data analysis and experimental verification of'microbe-immune', and finds that the phosphoketolase-producing bacteria can regulate host immune metabolic microenvironment, actively stabilize blood drug concentration of the anti-TNF monoclonal antibody and reduce immunogenicity, so as to achieve the purposes of stabilizing blood drug concentration of the anti-TNF monoclonal antibody and delaying clearance, significantly improve clinical response rate and remission rate, and is particularly suitable for a patient population with primary non-response or secondary non-response to the anti-TNF monoclonal antibody, thereby providing an effective solution for solving this clinical difficulty.

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The invention relates to preparation of a cyclic adenosine monophosphate (cAMP) detection kit by using a chemiluminescence immunoassay technology. Cyclic adenosine monophosphate is an important second messenger for cell signal transduction and has wide physiological functions. Cyclic adenosine monophosphate is small in molecular weight and poor in immunogenicity, so that when a corresponding antibody is prepared, a proper derivative site needs to be selected firstly, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic adenosine monophosphate hapten, preparation of a cyclic adenosine monophosphate complete antigen and an anti-cyclic adenosine monophosphate antibody, a method for measuring the concentration of cyclic adenosine monophosphate, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic adenylate derivative. The cyclic adenylic acid derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention discloses a composition for improving the immunity of aquatic organisms, and particularly belongs to the field of functional feeds, and the composition for improving the immunity of aquatic organisms comprises the following components in parts by mass: 20-30 parts of sedum sarmentosum extract, 30-40 parts of chenopodium ambrosioides extract and 10-15 parts of perilla frutescens extract. The composition further comprises 4-6 parts by mass of astaxanthin and 7-9 parts by mass of vitamin C phosphate. In the composition provided by the invention, the sedum sarmentosum extract, the chenopodium ambrosioides extract and the perilla frutescens extract have a certain synergistic effect in the aspect of improving the immunity of tilapia mossambica, and after astaxanthin and vitamin C phosphate are added into the composition, the effect is better. The feed containing the composition for improving the immunity of aquatic organisms can significantly improve the non-specific immunity of tilapia mossambica.

The invention relates to the technical field of electrochemical immunosensors, and provides an MXene (at) PANI (at) Au composite material and application thereof in detection of sepsis biomarkers. Through research and development of the MXene-coated PANI-coated Au composite material, the problems of high operation complexity, high cost, potential cross reaction, need of professional operation and need of detection in a specific place in the current detection process are solved. According to the MXene-coated PANI-coated Au biological immunosensor disclosed by the invention, the two electrodes can share the same sample, the same time and the same detection environment. The results of the two markers can be obtained at the same time through one-time sample adding. The method not only realizes fast, but also shortens the total detection time fundamentally, which has revolutionary significance for clinical scenes needing fast diagnosis.

The invention belongs to the technical field of biological immunity, and particularly relates to a monoclonal antibody for resisting pseudorabies virus gC protein and application of the monoclonal antibody. The affinity of the anti-PRV monoclonal antibody is greater than or equal to 5 * 10 < 9 > L / mol, the ELISA titer is greater than or equal to 1: 5.12 * 10 < 5 >, the IPMA titer is 1: 6.4 * 10 < 3 >, and the anti-PRV monoclonal antibody has the characteristic of high sensitivity. And the kit is suitable for various detection platforms such as ELISA, IPMA, Western Blot and the like, and a reliable tool is provided for rapid detection of the PRV antigen.

The invention relates to preparation of a Uric acid detection kit by using a chemiluminescence immunoassay technology. Uric acid is small in molecular weight, poor in immunogenicity and many in-vivo analogues, so that an antibody prepared from a uric acid derivative designed by the uric acid is poor in specificity and is difficult to meet reagent detection requirements. According to the present invention, allantoin is innovatively used to prepare the hapten and the antibody, in the detection process, the uric acid in the sample only needs to be converted into the allantoin through the specific sample treatment liquid, and the content of the uric acid in the body is indirectly reflected by determining the concentration of the allantoin in the sample; the invention mainly relates to design and synthesis of an allantoin hapten, preparation of an allantoin complete antigen and an anti-allantoin antibody, a method for measuring the concentration of uric acid, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of an allantoin derivative. The allantoin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention relates to a Trop2 antibody or an antigen binding fragment thereof and application thereof, and belongs to the technical field of biological immunotherapy, the antibody has good safety and a Trop2-targeting treatment effect, can be used for preparing a Trop2-targeting immune effector cell, and provides a treatment or improvement approach for diseases related to Trop2 expression.

This invention discloses a monoclonal antibody against RSV NS2 protein and its applications, relating to the field of bioimmunotechnology. The monoclonal antibody comprises the following amino acid sequences: CDR-H1 (SEQ ID NO. 7), CDR-H2 (SEQ ID NO. 9), CDR-H3 (SEQ ID NO. 11), CDR-L1 (SEQ ID NO. 14), CDR-L2 (LVS), and CDR-L3 (SEQ ID NO. 17). This monoclonal antibody can specifically bind to the RSV NS2 protein and can be applied to various detection methods for RSV NS2 protein, providing an important research tool for studying RSV infection mechanisms and establishing related detection technologies.

The invention relates to a bionic immune dynamic defense algorithm applied to the aspect of text map privacy protection. Aiming at the limitations of the existing generative model in privacy protection and against attack defense, the invention realizes active and adaptive protection of privacy risks by simulating a biological immune mechanism, and mainly comprises the following steps of: processing cue words by using an epigenetic coding technology to enhance the privacy protection capability of text embedding; identifying and evaluating a potential privacy risk through a privacy detection unit, and dynamically disturbing a potential space of the text graph model according to a risk level; the immune memory module is used for storing and recalling a historical threat mode so as to improve the response efficiency to repeated attacks; and when the risk is continuously higher than a preset threshold value, triggering a component operation mechanism, and selectively adjusting or disabling the model component to quickly block high risk generation. Compared with the prior art, the privacy protection capability and the antagonistic robustness can be remarkably improved while the image generation quality is maintained, and the balance between the performance and the safety is realized.

The invention relates to a preparation method of a lactic acid (lactic acid) detection kit by using a chemiluminescence immunoassay technology. As lactic acid is small in molecular weight and poor in immunogenicity, when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a lactic acid hapten, preparation of a lactic acid complete antigen and an anti-lactic acid antibody, a method for measuring the concentration of lactic acid, and composition and components of a reagent. The lactic acid derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention belongs to the technical field of biological immunodetection and nano sensing, and particularly discloses a colorimetric / SERS (Surface Enhanced Raman Scattering) dual-mode detection method for a digestive tract tumor marker based on gold coral at platinum nano enzyme, which comprises the following steps: preparing an Au NCs at Pt nano enzyme probe labeled with a labeled antibody (Ab2); the method comprises the following steps: mixing and incubating a sample to be detected, a nano-enzyme probe and a magnetic bead coated with a capture antibody (Ab1) in an optimized incubation solution, and forming an immune sandwich compound through a specific immune reaction; carrying out magnetic separation and washing on the immune sandwich compound, and finally concentrating and fixing the volume to a small volume; adding an enzyme substrate TMB (Tetramethylbenzidine) solution, and catalyzing TMB to be oxidized into oxTMB by utilizing peroxidase-like activity of the nano-enzyme; and S5, observing the color change of the oxTMB by adopting a colorimetric method and detecting a characteristic Raman signal by adopting SERS (Surface Enhanced Raman Scattering), so as to realize rapid, high-sensitivity and high-specificity dual-mode detection on the CA19-9. According to the method, the detection sensitivity and efficiency are remarkably improved by utilizing the excellent catalysis and SERS enhancement dual effects of the Au NCs (at) Pt nano-enzyme and combining a magnetic bead separation and enrichment technology.

The application relates to a preparation of a galactose detection kit by using a chemiluminescence immunoassay technique. Since the galactose has small molecular weight, poor immunogenicity, strong immunological tolerance, and has a D / L chiral structure, exists in a six-membered ring form in a solution, and can be converted into alpha and beta anomers. Therefore, when preparing a corresponding antibody, firstly, a suitable anomer and a derivative site need to be selected, and a derived hapten and a specific macromolecular carrier are coupled to prepare a complete antigen. The application successfully prepares an antibody with good specificity and strong affinity by designing and reforming the hapten. The application mainly relates to the design and synthesis of a galactose hapten, the preparation of a galactose complete antigen and an anti-galactose antibody, and a method for determining the concentration of galactose, the composition and ingredients of a reagent. The galactose derivative has the structure shown in formula (I).

The invention relates to a preparation method of a prourobilinogen (Urobilinogen) detection kit by using a chemiluminescence immunoassay technology. Joint detection of the prourobilirubin and the bilirubin is an important basis for clinically judging intrahepatic cholestasis, completely obstructive jaundice and hepatitis, and is also an important index of liver functions. Due to small molecular weight and poor immunogenicity of the urobilinogen, when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. The invention mainly relates to design and synthesis of a urobilisin hapten, preparation of a urobilisin complete antigen and an anti-urobilisin antibody, a method for measuring the concentration of urobilisin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise the design and chemical synthesis of a urobilinogen derivative. The urobilinogen derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention discloses an anti-human P14 polypeptide rabbit monoclonal antibody and application thereof, and relates to the technical field of biological immunodetection, the anti-human P14 polypeptide rabbit monoclonal antibody comprises a first group: SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, DAS and SEQ ID NO.5; or, a second group: SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, DAS, and SEQ ID NO. 10; or, a third group: SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, DTS and SEQ ID NO.15. The invention also discloses a method for preparing the traditional Chinese medicine composition. The anti-human P14 polypeptide rabbit monoclonal antibody disclosed by the invention can specifically recognize the human P14 polypeptide and can be widely applied to detection of the human P14 polypeptide.

The application discloses an inhibitory antibody or antigen-binding fragment thereof against human OX40, a preparation method and application, and belongs to the technical field of biological immunity. The human-mouse chimeric antibody Y07-L2 and the humanized antibody Y07-C2 prepared by the application have similar EC50 in combination with human OX40, and are similar to the targeted antibody drug KHK-4083 in inhibiting OX40. The heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is shown as SEQ ID NO. 14, and the light chain variable region is shown as SEQ ID NO. 15; the heavy chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 20, and the light chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 21; the CDR region of the humanized antibody Y07-C2 is subjected to mutation, and the mutant antibody Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The invention relates to a preparation method of a gamma-aminobutyric acid (gamma-aminobutyric acid) detection kit by using a chemiluminescence immunoassay technology. Due to the fact that gamma-aminobutyric acid is small in molecular weight and poor in immunogenicity, the specificity and affinity of the prepared antibody cannot meet the requirements of an immunodetection reagent, and 4-acetaminobutyric acid with the large molecular weight is innovatively used for hapten design. In the detection process, gamma-aminobutyric acid in a sample is converted into 4-acetaminobutyric acid only by acetylation treatment through a specific sample treatment solution, and the content of gamma-aminobutyric acid in the body is indirectly reflected by measuring the concentration of 4-acetaminobutyric acid in the sample. The invention mainly relates to design and synthesis of a gamma-aminobutyric acid hapten, preparation of a gamma-aminobutyric acid complete antigen and an anti-gamma-aminobutyric acid antibody, a method for measuring the concentration of gamma-aminobutyric acid, and composition and components of a reagent. The gamma-aminobutyric acid derivative disclosed by the invention has a structure as shown in a formula (I).

This invention relates to a method for preparing a levodopa detection kit using chemiluminescent immunoassay. Due to the small molecular weight and poor immunogenicity of levodopa, and its presence of catechol in its structure, it is easily oxidized in neutral or alkaline environments. Therefore, when preparing the corresponding antibody, it is necessary to first select a suitable derivatization site and conjugate the derived hapten to a specific macromolecular carrier to prepare the complete antigen. This invention successfully prepared antibodies with good specificity and strong affinity through the design and modification of the hapten. This invention mainly relates to the design and synthesis of levodopa haptens, the preparation of complete levodopa antigens and anti-levodopa antibodies, and the methods, reagent composition, and components for determining levodopa concentration. The hapten design and synthesis of this invention mainly includes the design and chemical synthesis of levodopa derivatives. The levodopa derivative of this invention has the structure shown in formula (I): Formula (I).

The invention belongs to the technical field of biological immunity, and provides a novel duck reovirus sigma C protein monoclonal antibody, the heavy chain of the monoclonal antibody is IgG1 type, and the light chain is Kappa chain. The number of positive hybridoma cells of the monoclonal antibody is three, and the positive hybridoma cells are named as 5B7, 3C10 and 6G11. And the positive hybridoma cell of the monoclonal antibody is 6G11. And the minimum epitope of the monoclonal antibody is 304 to 314 aa. According to the present invention, the NDRV recombinant sigma C protein is expressed, the hybridoma technology is adopted to obtain the monoclonal antibody with high titer and good activity, the monoclonal antibody is adopted to screen and identify the novel antigen epitope 304WQDLVPVWLQ314 of the NDRV, and the epitope has high conservative property in the NDRV strain, and is the specific antigen epitope of the NDRV;

The invention relates to the technical field of biochemistry and molecular immunology, in particular to a mycoplasma capricolum subsp. Capricolum RS02020 protein polyclonal antibody, the polyclonal antibody is prepared by carrying out biological immunization on a recombinant protein RS02020 coded and expressed by a recombinant plasmid pET28a-RS02020, and a coding gene sequence of the recombinant plasmid pET28a-RS02020 is a nucleotide sequence shown in SEQ ID NO.1 in a sequence table. The invention relates to a preparation method of a mycoplasma capricolum subsp. Capricolum RS02020 protein polyclonal antibody. The preparation method comprises the following steps: S1, constructing a recombinant plasmid pET28a-RS02020; S2, carrying out prokaryotic expression and purification on an RS02020 protein; and S3, polyclonal antibody preparation and titer determination. Through bioinformatics analysis, subcellular localization, transmembrane helix, antigenicity and hydrophilic characteristics of the Mccp protein RS020202 are provided, soluble efficient expression is tested in escherichia coli, and high-purity RS02020 recombinant protein is obtained; the prepared polyclonal antibody is high in titer and good in specificity, and can be applied to functional research of proteins and further evaluation of CCPP antigens.

This invention belongs to the field of bioimmunotechnology, specifically relating to an anti-VZV gC protein monoclonal antibody and its preparation and application. The anti-VZV gC protein monoclonal antibody of this invention can be applied to immunological detection and can also facilitate the development of vaccines based on the VZV gC protein. This invention also provides a simple and convenient method for preparing the anti-VZV gC protein monoclonal antibody. The anti-VZV gC protein monoclonal antibody comprises the following sequences or their active modification sequences (e.g., addition, deletion, substitution): the heavy chain variable region nucleotide sequence as shown in SEQ ID NO.1; the heavy chain variable region amino acid sequence as shown in SEQ ID NO.2; the light chain variable region nucleotide sequence as shown in SEQ ID NO.3; and the light chain variable region amino acid sequence as shown in SEQ ID NO.4. This invention also provides the application of the anti-VZV gC protein monoclonal antibody in the preparation of VZV detection reagents or kits, and the application of the anti-VZV gC protein monoclonal antibody in the preparation of vaccines.

The application discloses an mRNA vaccine mechanism preparation method of pseudorabies virus and belongs to the technical field of biological immunity. The technical scheme is as follows: an mRNA vaccine of pseudorabies virus, wherein the antigen coding sequence of the vaccine is obtained according to the gE protein sequence of the pseudorabies virus. The mRNA vaccine is obtained by taking the gE protein of the pseudorabies virus, which is usually neglected in the preparation of vaccines in the prior art, as the design basis of the antigen. The mRNA vaccine obtained by referring to the design is tested, and the test result shows that the mRNA vaccine is relatively other pseudorabies.

The application discloses a varicella-zoster virus gL protein monoclonal antibody and application thereof, and relates to the technical field of biological immunity. The varicella-zoster virus gL protein monoclonal antibody comprises CDR-H1 with an amino acid sequence as shown in SEQ ID NO. 9, CDR-H2 with an amino acid sequence as shown in SEQ ID NO. 11, CDR-H3 with an amino acid sequence as shown in SEQ ID NO. 13, CDR-L1 with an amino acid sequence as shown in SEQ ID NO. 16, CDR-L2 with an amino acid sequence of LVS and CDR-L3 with an amino acid sequence as shown in SEQ ID NO. 19. The monoclonal antibody provided by the application can be specifically combined with the varicella-zoster virus gL protein, can be applied to the preparation of products for detecting the varicella-zoster virus gL protein or the varicella-zoster virus gL antibody, and has important application value.

The application belongs to the technical field of biological immunotherapy, and particularly relates to a retinoblastoma protein mutant and a preparation method and application thereof. The retinoblastoma protein mutant comprises a CDK phosphorylation site mutant retinoblastoma protein 1 mutant polypeptide, a CDK phosphorylation site mutant retinoblastoma protein 1 mutant protein or a CDK phosphorylation site mutant retinoblastoma protein 1 mutant analog. The RB1 is improved for long-term binding to E2F family transcription factors, the cell cycle is delayed, the expression of E2F target genes is significantly inhibited, and the proliferation and growth of cancer cells are significantly inhibited.

The invention relates to a preparation method of an adrenalin detection kit by using a chemiluminescence immunoassay technology. Because epinephrine is small in molecular weight and poor in immunogenicity, the structure of epinephrine contains catechol, and epinephrine is extremely easy to oxidize in a neutral or alkaline environment, when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of an epinephrine hapten, preparation of an epinephrine complete antigen and an anti-epinephrine antibody, a method for measuring the concentration of epinephrine, and composition and components of a reagent. The epinephrine derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention relates to a preparation method of a bilirubin detection kit by using a chemiluminescence immunoassay technology. Bilirubin is an important basis for clinically judging jaundice and is also an important index of liver functions. As bilirubin is small in molecular weight and poor in immunogenicity, when a corresponding antibody is prepared, a proper derivative site needs to be selected firstly, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a bilirubin hapten, preparation of a bilirubin complete antigen and an anti-bilirubin antibody, a method for determining the concentration of bilirubin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of bilirubin derivatives. The bilirubin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention discloses an immune cell carrier protective agent which is a retrovirus carrier, and belongs to the technical field of biological immunotherapy. The method involves a specific formulation of a retroviral vector centrifugation protective agent and a resuspension protective agent. The method comprises the following steps: resuscitating a PG13 toxin-producing cell strain, carrying out cell passage amplification culture, filtering a virus solution, mixing with a centrifugal protective agent, centrifuging, resuspending virus particles by using a resuspending protective agent, cryopreserving and the like, so that many problems of a traditional retrovirus vector concentration and purification method are effectively solved. Experiments show that the method can significantly improve the titer (about 3-4 times) of the retrovirus vector, greatly reduce bovine serum albumin (BSA) residue (about 99%), host DNA residue (about 65%) and host protein residue (about 99%), has important significance in the field of biological immunotherapy, and can provide powerful support for preparation of high-quality retrovirus.